Premium
Identification and Directed Development of Non‐Organic Catalysts with Apparent Pan‐Enzymatic Mimicry into Nanozymes for Efficient Prodrug Conversion
Author(s) -
Walther Raoul,
Winther Anna K.,
Fruergaard Anne Sofie,
van den Akker Wouter,
Sørensen Lise,
Nielsen Signe Maria,
Jarlstad Olesen Morten T.,
Dai Yitao,
Jeppesen Henrik S.,
Lamagni Paolo,
Savateev Aleksandr,
Pedersen Søren Lykke,
Frich Camilla Kaas,
VigierCarrière Cécile,
Lock Nina,
Singh Mandeep,
Bansal Vipul,
Meyer Rikke L.,
Zelikin Alexander N.
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201812668
Subject(s) - prodrug , chemistry , context (archaeology) , enzyme , mimicry , combinatorial chemistry , biochemistry , nanotechnology , biology , materials science , ecology , paleontology
Abstract Nanozymes, nanoparticles that mimic the natural activity of enzymes, are intriguing academically and are important in the context of the Origin of Life. However, current nanozymes offer mimicry of a narrow range of mammalian enzymes, near‐exclusively performing redox reactions. We present an unexpected discovery of non‐proteinaceous enzymes based on metals, metal oxides, 1D/2D‐materials, and non‐metallic nanomaterials. The specific novelty of these findings lies in the identification of nanozymes with apparent mimicry of diverse mammalian enzymes, including unique pan‐glycosidases. Further novelty lies in the identification of the substrate scope for the lead candidates, specifically in the context of bioconversion of glucuronides, that is, human metabolites and privileged prodrugs in the field of enzyme‐prodrug therapies. Lastly, nanozymes are employed for conversion of glucuronide prodrugs into marketed anti‐inflammatory and antibacterial agents, as well as “nanozyme prodrug therapy” to mediate antibacterial measures.